Detalles de la búsqueda
1.
Leukocyte extravasation and vascular permeability are each controlled in vivo by different tyrosine residues of VE-cadherin.
Nat Immunol
; 15(3): 223-30, 2014 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-24487320
2.
RE-MIND2: comparative effectiveness of tafasitamab plus lenalidomide versus polatuzumab vedotin/bendamustine/rituximab (pola-BR), CAR-T therapies, and lenalidomide/rituximab (R2) based on real-world data in patients with relapsed/refractory diffuse large B-cell lymphoma.
Ann Hematol
; 102(7): 1773-1787, 2023 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-37171597
3.
A phase 2a, single-arm, open-label study of tafasitamab, a humanized, Fc-modified, anti-CD19 antibody, in patients with relapsed/refractory B-precursor cell acute lymphoblastic leukemia.
Cancer
; 127(22): 4190-4197, 2021 11 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-34343354
4.
Correction to: REMIND2: comparative effectiveness of tafasitamab plus lenalidomide versus polatuzumab vedotin/bendamustine/rituximab (polaBR), CART therapies, and lenalidomide/rituximab (R2) based on realworld data in patients with relapsed/refractory diffuse large Bcell lymphoma.
Ann Hematol
; 102(9): 2643-2644, 2023 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-37432417
5.
Improved Efficacy of Tafasitamab plus Lenalidomide versus Systemic Therapies for Relapsed/Refractory DLBCL: RE-MIND2, an Observational Retrospective Matched Cohort Study.
Clin Cancer Res
; 28(18): 4003-4017, 2022 09 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-35674661
6.
RE-MIND: Comparing Tafasitamab + Lenalidomide (L-MIND) with a Real-world Lenalidomide Monotherapy Cohort in Relapsed or Refractory Diffuse Large B-cell Lymphoma.
Clin Cancer Res
; 27(22): 6124-6134, 2021 11 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-34433649
7.
MOR202, a novel anti-CD38 monoclonal antibody, in patients with relapsed or refractory multiple myeloma: a first-in-human, multicentre, phase 1-2a trial.
Lancet Haematol
; 7(5): e381-e394, 2020 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-32171061
8.
Dissociation of VE-PTP from VE-cadherin is required for leukocyte extravasation and for VEGF-induced vascular permeability in vivo.
J Exp Med
; 208(12): 2393-401, 2011 Nov 21.
Artículo
en Inglés
| MEDLINE | ID: mdl-22025303
9.
Cell adhesion dynamics at endothelial junctions: VE-cadherin as a major player.
Trends Cell Biol
; 19(1): 8-15, 2009 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-19010680
10.
VE-PTP controls blood vessel development by balancing Tie-2 activity.
J Cell Biol
; 185(4): 657-71, 2009 May 18.
Artículo
en Inglés
| MEDLINE | ID: mdl-19451274
11.
VE-PTP maintains the endothelial barrier via plakoglobin and becomes dissociated from VE-cadherin by leukocytes and by VEGF.
J Exp Med
; 205(12): 2929-45, 2008 Nov 24.
Artículo
en Inglés
| MEDLINE | ID: mdl-19015309
12.
Angiopoietins assemble distinct Tie2 signalling complexes in endothelial cell-cell and cell-matrix contacts.
Nat Cell Biol
; 10(5): 527-37, 2008 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-18425119
Resultados
1 -
12
de 12
1
Próxima >
>>